Clinical predictors of drug nonresponse in obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 66, Issue 12, 2005, Pages 1517-1523

  Shetti, Chandrashekhar N ^a   Reddy, Y C Janardhan ^a   Kandavel, Thennarasu ^a   Kashyap, Kartik ^a   Singisetti, Srinivas ^a   Hiremath, Avinash S ^a   Siddequehusen, Mulia Umar Faruq ^a   Raghunandanan, Samar ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGORAPHOBIA; ALCOHOL ABUSE; ARTICLE; BEHAVIOR THERAPY; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CHRONIC DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; COMORBIDITY; COMPULSION; DEMOGRAPHY; DISEASE DURATION; DYSTHYMIA; EATING DISORDER; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; INDIA; INTROSPECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PANIC; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REGRESSION ANALYSIS; SOCIAL PHOBIA; SOMATOFORM DISORDER; SUBSTANCE ABUSE; TIC; UNIVARIATE ANALYSIS;

EID: 30344437301     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1204     Document Type: Article

References (48)

1. Abramowitz J. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65:44-52
2. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
3. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995;166:424-443
4. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-106
5. Ackerman DL, Greenland S, Bystritsky A, et al. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247-254
6. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:11-18
7. Erzegovesi S, Cavallini MC, Cavadeni P, et al. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:488-492
8. Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995;56:368-373
9. Alarcon RD, Libb JW, Spitler D. A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol 1993;13:210-213
10. Jenike MA. Management of patients with treatment-resistant obsessive-compulsive disorder. In: Pato MT, Zohar J, eds. Current Treatments of Obsessive-Compulsive Disorder. Washington, DC: American Psychiatric Press; 1991:135-155
11. Ravi Kishore V, Samar R, Janardhan Reddy YC, et al. Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur Psychiatry 2004;19:202-208
12. Leonard HL, Swedo SE, Lenane MC, et al. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993;50:429-439
13. Jenike MA, Baer L, Minichiello WE, et al. Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 1986;143:530-532
14. Baer L, Jenike MA, Black DW, et al. Effect of Axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:862-866
15. Capstick N, Seldrup J. Phenomenological aspects of obsessional patients treated with clomipramine. Br J Psychiatry 1973;122:719-720
16. Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals, I. Br J Psychiatry 1980;136:1-25
17. Overbeek T, Schruers K, Vermetten E, et al. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry 2002;63:1106-1112
18. DeVeaugh-Geiss J, Katz R, Landau P, et al. Clinical predictors of treatment response in obsessive-compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharmacol Bull 1990;26:54-59
19. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, and placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-29
20. Katz RJ, DeVeaugh-Geiss J. The antiobsessional effects of clomipramine do not require concomitant affective disorder. Psychiatry Res 1990;26:54-59
21. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
22. Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state of the art treatment. J Clin Psychiatry 2002;63(suppl 6):20-29
23. Pallanti S, Hollander E, Bienstock C, et al. Treatment nonresponse in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
25. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (YBOCS), 1: development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011
26. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (YBOCS), 2: validity. Arch Gen Psychiatry 1989;46:1012-1016
27. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992
28. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1995
29. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1997
30. Paul DL, Hurst CR. Schedule for Tourette and Other Behavioral Syndromes: Adult version A3. Yale Family Genetic Study of Tourette Syndrome. New Haven, Conn: Yale Child Study Center; 1996
31. Eisen JL, Phillips KA, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 1998;155:102-108
32. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
34. Eisen JL, Rasmussen SA, Phillips KA, et al. Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry 2001;42:494-497
35. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309-317
36. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder, 1: a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285
37. Skoog G, Skoog I. A 40 year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1999;56:121-127
38. Buchanan AW, Meng KS, Marks IM. What predicts improvement and compliance during the behavioral treatment of obsessive-compulsive disorder? Anxiety 1996;2:22-27
39. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-44
40. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
41. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 1992;53(suppl 4):4-10
42. Jaisoorya TS, Janardhan Reddy YC, Srinath S. Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? findings from an Indian study. Eur Child Adolesc Psychiatry 2003;12:290-297
43. Marks I. Are there anticompulsive or antiphobic drugs? review of the evidence. Psychopharmacol Bull 1982;18:78-84
44. Hollander E, Mullen L, DeCaria CM, et al. Obsessive-compulsive disorder, depression, and fluoxetine. J Clin Psychiatry 1991;52:418-422
45. Foa EB. Failure in treating obsessive-compulsives. Behav Res Ther 1979;17:169-176
46. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-585
47. Reddy YCJ, D'Souza SM, Shetti C, et al. An 11- to 13-year follow-up of 75 subjects with obsessive-compulsive disorder. J Clin Psychiatry 2005;66:744-749
48. Sobin C, Blundell ML, Weiller F, et al. Evidence of a schizotypy subtype in OCD. J Psychiatr Res 2000;34:15-24